|
25 Sep 2025 |
Laurus Labs
|
Consensus Share Price Target
|
896.35 |
694.85 |
- |
-22.48 |
hold
|
|
|
|
|
27 Jan 2025
|
Laurus Labs
|
BOB Capital Markets Ltd.
|
896.35
|
488.00
|
534.65
(67.65%)
|
45.56 |
Sell
|
|
|
Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps
|
|
25 Jan 2025
|
Laurus Labs
|
Motilal Oswal
|
896.35
|
720.00
|
602.65
(48.73%)
|
Target met |
Buy
|
|
|
Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.
|
|
25 Oct 2024
|
Laurus Labs
|
BOB Capital Markets Ltd.
|
896.35
|
305.00
|
465.80
(92.43%)
|
65.97 |
Sell
|
|
|
Earnings miss for 2Q on our and street estimates on all fronts. Revenue/PAT came short of consensus estimates by -5%/39%
|
|
24 Oct 2024
|
Laurus Labs
|
Motilal Oswal
|
896.35
|
530.00
|
447.30
(100.39%)
|
Target met |
Buy
|
|
|
Laurus Lab (LAURUS) delivered largely in-line operational performance for 2QFY25. It witnessed an improving traction in the CDMO business, with a 33%/44% YoY/QoQ jump in sales for 2QFY25.
|
|
29 Jul 2024
|
Laurus Labs
|
Keynote Capitals Ltd
|
896.35
|
456.00
|
451.00
(98.75%)
|
Target met |
Neutral
|
|
|
Quarterly Update Q1FY25
|
|
25 Jul 2024
|
Laurus Labs
|
Motilal Oswal
|
896.35
|
505.00
|
433.85
(106.60%)
|
Target met |
Buy
|
|
|
Laurus Labs (LAURUS) posted a weak 1QFY25 due to deviation in buying of ARV formulations and deferral of some orders in the other API segment.
|
|
29 Apr 2024
|
Laurus Labs
|
Keynote Capitals Ltd
|
896.35
|
445.00
|
443.75
(101.99%)
|
Target met |
Neutral
|
|
|
Quarterly Update Q4FY24
|
|
25 Apr 2024
|
Laurus Labs
|
Motilal Oswal
|
896.35
|
480.00
|
425.90
(110.46%)
|
Target met |
Buy
|
|
|
Laurus Labs (LAURUS) delivered better-than-expected revenue in 4QFY24. However, EBITDA/PAT missed our estimates due to lower sales in the CDMO segment and weak pricing in the other API segment.
|
|
29 Jan 2024
|
Laurus Labs
|
BOB Capital Markets Ltd.
|
896.35
|
305.00
|
374.20
(139.54%)
|
|
Sell
|
|
|
BJAUT: Healthy revival but priced in; downgrade to SELL. TVSL: On a fast track raise to BUY. SBICARD: Asset quality concerns persist; downgrade to HOLD. LAURUS: Challenges galore cut to SELL. CIPLA: Healthy revenue growth, strong margins. MAHGL: Volume growth accelerating, reiterate BUY. DCBB: NII sequentially flat on high interest cost. SBILIFE: ULIP-led growth; maintains market leadership
|
|
25 Jan 2024
|
Laurus Labs
|
BOB Capital Markets Ltd.
|
896.35
|
305.00
|
378.80
(136.63%)
|
|
Sell
|
|
|
Fourth straight quarterly miss with upsets on all fronts; Q3 revenue/ EBITDA well short of Bloomberg consensus by 13%/79%
|
|
25 Jan 2024
|
Laurus Labs
|
Keynote Capitals Ltd
|
896.35
|
423.00
|
378.80
(136.63%)
|
Target met |
Buy
|
|
|
Quarterly Update Q3FY24
|
|
25 Jan 2024
|
Laurus Labs
|
Motilal Oswal
|
896.35
|
440.00
|
378.80
(136.63%)
|
Target met |
Buy
|
|
|
|
|
23 Oct 2023
|
Laurus Labs
|
Keynote Capitals Ltd
|
896.35
|
447.00
|
362.40
(147.34%)
|
Target met |
Buy
|
|
|
Quarterly Update Q2FY24
|
|
20 Oct 2023
|
Laurus Labs
|
Sharekhan
|
896.35
|
293.00
|
362.40
(147.34%)
|
|
Sell
|
|
|
|
|
31 Jul 2023
|
Laurus Labs
|
Keynote Capitals Ltd
|
896.35
|
402.00
|
352.00
(154.64%)
|
Target met |
Buy
|
|
|
Quarterly Update Q1FY24
|
|
02 May 2023
|
Laurus Labs
|
Keynote Capitals Ltd
|
896.35
|
383.00
|
311.60
(187.66%)
|
Target met |
Buy
|
|
|
Quarterly Update Q4FY23
|
|
28 Apr 2023
|
Laurus Labs
|
ICICI Direct
|
896.35
|
300.00
|
307.60
(191.40%)
|
Target met |
Hold
|
|
|
|
|
31 Mar 2023
|
Laurus Labs
|
Keynote Capitals Ltd
|
896.35
|
396.00
|
292.95
(205.97%)
|
Target met |
Buy
|
|
|
Initiating Coverage Report
|
|
31 Jan 2023
|
Laurus Labs
|
ICICI Direct
|
896.35
|
400.00
|
330.30
(171.37%)
|
Target met |
Buy
|
|
|
|
|
30 Jan 2023
|
Laurus Labs
|
Motilal Oswal
|
896.35
|
440.00
|
341.80
(162.24%)
|
Target met |
Buy
|
|
|
|